MedTrace Logo

Personalized Cellular Vaccine for Brain Metastases (PERCELLVAC3)

NCT02808416 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2022-05-27

No results posted yet for this study

Summary

Cancer patients with brain metastases (BM) have poor prognosis. Current treatments produce limited efficacy. Recent advance in cancer immunotherapy has provided important new means to treat cancer patients at advanced stages. This study is designed to perform a clinical trial to treat advanced caner patients with brain metastases with personalized dendritic cell-based cellular vaccines. The patients will receive vaccines consisting of mRNA tumor antigen pulsed DCs. Immune response to the immunized tumor antigens will be monitored. Safety and efficacy will be observed in this study.

Conditions

Interventions

BIOLOGICAL

Personalized cellular vaccine

Cancer patients with brain metastases will undergo tumor resection or biopsy, and receive tumor antigen mRNA pulsed cellular vaccines. Other Names: • Tumor antigen pulsed DC and PBMC, autologous tumor vaccine

Sponsors & Collaborators

  • Beijing Tricision Biotherapeutics Inc

    collaborator INDUSTRY

  • Zhuhai Trinomab Pharmaceutical Co., Ltd.

    collaborator INDUSTRY

  • Jinan University Guangzhou

    collaborator OTHER

  • Guangdong 999 Brain Hospital

    lead OTHER

Principal Investigators

  • Jian Zhang, M.D. · Guangdong 999 Brain Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-03-01
Primary Completion
2017-10-31
Completion
2019-06-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02808416 on ClinicalTrials.gov